Facts of Interest:
American Well (NYSE:AMWL) was the largest firm by market cap to set a new 52-week low.
Phio Pharmaceuticals (NASDAQ:PHIO) was the smallest company when considering market cap to set a new 52-week low.
Kiromic BioPharma (NASDAQ:KRBP) was the biggest loser of the morning session, as it dropped 15.84% to reach its new 52-week low.
Here are all the stocks that set new 52-week lows during the first half-hour of trading on Thursday:
American Well (NYSE:AMWL) shares reached a new 52-week low of $11.60 on Thursday morning, moving down 7.18%.
Berkeley Lights (NASDAQ:BLI) shares moved down 1.64% on Thursday to hit a new 52-week low of $37.91, drifting down 1.64%.
Buffalo, N.Y. (PRWEB) May 12, 2021 - Dr. Kalinski has attracted more than $22.5 million in active grants- His innovations have potential to significantly
Designer alterations to brain cells reduce anxious behavior in monkeys
Using a technique that could point to a new way to help people with severe anxiety and other treatment-resistant psychiatric illnesses, researchers at the University of Wisconsin–Madison successfully dialed down anxious monkeys’ overactive response to a potential threat by installing a custom chemical switch in their brain cells.
About 30 percent of people with anxiety and mood disorders do not find sufficient relief in available treatments like medications and psychotherapy, leaving many to live with severe and chronic symptoms of anxiety and depression, and a significant risk of suicide. Some of them are helped by more invasive treatment options including deep brain stimulation, in which small electrodes are implanted deep into the brain.
Date Time
Designer alterations to brain cells reduce anxious behavior in monkeys, hold promise for new treatments
Using a technique that could point to a new way to help people with severe anxiety and other treatment-resistant psychiatric illnesses, researchers at the University of Wisconsin-Madison successfully dialed down anxious monkeys’ overactive response to a potential threat by installing a custom chemical switch in their brain cells.
About 30 percent of people with anxiety and mood disorders do not find sufficient relief in available treatments like medications and psychotherapy, leaving many to live with severe and chronic symptoms of anxiety and depression, and a significant risk of suicide. Some of them are helped by more invasive treatment options including deep brain stimulation, in which small electrodes are implanted deep into the brain.
Biogen, Capsigen Launch Up-to-$1.3B AAV Capsid Collaboration
May 11, 2021
Share
Biogen will partner with Capsigen to engineer novel adeno-associated virus (AAV) capsids for gene therapies designed to treat CNS and neuromuscular disorders, through a strategic research collaboration that could generate more than $1.3 billion for Capsigen.
The companies said they will create and identify novel AAV capsids tailored to meet disease-specific transduction profiles through their collaboration, designed to combine Capsigen’s Transcription-Dependent Directed Evolution (TRADE™) platform and associated technologies with Biogen’s discovery, development, manufacturing, and commercialization capabilities.
Capsigen’s technology is designed to produce dose optimized, fit for purpose vectors that may have applicability across Biogen’s gene therapy pipeline.